Claims for Patent: 9,399,777

Summary for Patent: 9,399,777

Title:	Methods and means for obtaining modified phenotypes
Abstract:	Methods and means are provided for reducing the phenotypic expression of a nucleic acid of interest in eukaryotic cells, particularly in plant cells, by providing aberrant, preferably unpolyadenylated, target-specific RNA to the nucleus of the host cell. Preferably, the unpolyadenylated target-specific RNA is provided by transcription of a chimeric gene comprising a promoter, a DNA region encoding the target-specific RNA, a self-splicing ribozyme and a DNA region involved in 3\' end formation and polyadenylation.
Inventor(s):	Waterhouse; Peter Michael (Canberra ACT, AU), Wang; Ming-Bo (Canberra ACT, AU)
Assignee:	Commonwealth Scientific & Industrial Research Organisation (Campbell, AU)
Application Number:	13/092,645
Patent Claims:	1. A method for reducing the phenotypic expression of a nucleic acid of interest, which is normally capable of being expressed in a plant cell, said method comprising: providing unpolyadenylated RNA to the nucleus of the cell, wherein the unpolyadenylated RNA is produced by transcription of a chimeric DNA comprised within said cell, said chimeric DNA comprising a promoter operably linked to a target-specific DNA region encoding said RNA, and wherein the unpolyadenylated RNA comprises a target-specific sense nucleotide sequence, a target-specific antisense nucleotide sequence, and a spacer nucleotide sequence located between said sense and antisense nucleotide sequence, wherein the target-specific antisense nucleotide sequence comprises 20 consecutive nucleotides having 100% sequence identity to a sequence complementary to a sequence of 20 consecutive nucleotides of an untranslated region of an RNA molecule transcribed or produced from said nucleic acid of interest, and wherein the target-specific sense nucleotide sequence and the target-specific antisense nucleotide sequence form an artificial hairpin structure with each other. 2. The method of claim 1, wherein the nucleic acid of interest is a gene incorporated in the genome of the cell. 3. The method of claim 1, wherein the nucleic acid of interest is an endogenous gene of the cell. 4. The method of claim 1, wherein the nucleic acid of interest is a transgene. 5. The method of claim 1, wherein the nucleic acid of interest is a viral nucleic acid. 6. The method of claim 1, wherein the target-specific sense nucleotide sequence comprises 20 consecutive nucleotides having 100% sequence identity to a sequence of 20 consecutive nucleotides of the RNA molecule transcribed or produced from the nucleic acid of interest. 7. The method of claim 1, wherein the unpolyadenylated RNA lacks a 5' cap structure. 8. The method of claim 1, wherein the unpolyadenylated RNA comprises a persistent intron that has been modified in its splice sites so as to prevent splicing. 9. The method of claim 1, wherein the chimeric DNA is transcribed to produce a first target-specific RNA, which is processed by the action of a ribozyme to produce the unpolyadenylated RNA. 10. The method of claim 1, wherein the promoter is a promoter recognized by RNA polymerase I. 11. The method of claim 1, wherein the promoter is a promoter recognized by RNA polymerase III. 12. The method of claim 1, wherein the cell is a cultured cell. 13. The method of claim 1, further comprising: (a) selecting a target sequence of at least 20 consecutive nucleotides within a nucleic acid of interest before (b) the step of providing unpolyadenylated RNA to the nucleus of the cell, which comprises introducing a chimeric DNA encoding said unpolyadenylated RNA into the nucleus of said cell comprising the nucleic acid of interest, and thereafter (c) observing a phenotype of said cell by a suitable method; thereby identifying a phenotype associated with the expression of the nucleic acid of interest in the cell. 14. The method of claim 13, wherein the phenotype associated with the expression of the nucleic acid of interest in the cell was previously unidentified. 15. The method of claim 13, wherein the phenotype is observed after culturing of the cells. 16. The method of claim 13, wherein the phenotype is a modified profile of metabolites synthesized in the cell. 17. A chimeric DNA molecule for reducing the phenotypic expression of a nucleic acid of interest that is normally capable of being expressed in a plant cell, said chimeric DNA molecule comprising a promoter which is operable in the cell, the promoter being operably linked to a sequence encoding an unpolyadenylated RNA capable of reducing expression of the nucleic acid of interest when provided to the nucleus of the cell, the unpolyadenylated RNA comprising: a target-specific sense nucleotide sequence, a target-specific antisense nucleotide sequence, and a spacer nucleotide sequence located between said sense and antisense nucleotide sequence, wherein the target-specific antisense nucleotide sequence comprises 20 consecutive nucleotides having 100% sequence identity to a sequence complementary to a sequence of 20 consecutive nucleotides of an untranslated region of an RNA molecule transcribed or produced from said nucleic acid of interest, wherein the target-specific sense nucleotide sequence and the target-specific antisense nucleotide sequence form an artificial hairpin structure with each other. 18. The chimeric DNA molecule of claim 17, wherein the nucleic acid of interest is a gene incorporated in the genome of the cell. 19. The chimeric DNA molecule of claim 17, wherein the nucleic acid of interest is an endogenous gene of the cell. 20. The chimeric DNA molecule of claim 17, wherein the nucleic acid of interest is a transgene. 21. The chimeric DNA molecule of claim 17, wherein the nucleic acid of interest is a viral nucleic acid. 22. The chimeric DNA molecule of claim 17, wherein the target-specific sense nucleotide sequence comprises 20 consecutive nucleotides having 100% sequence identity to a sequence of 20 consecutive nucleotides of the RNA molecule transcribed or produced from the nucleic acid of interest. 23. The chimeric DNA molecule of claim 17, wherein the promoter is a promoter recognized by RNA polymerase I. 24. The chimeric DNA molecule of claim 17, wherein the promoter is a promoter recognized by RNA polymerase III. 25. A plant or fungal cell, comprising a chimeric DNA molecule comprising: a promoter that is operable in the cell, the promoter being operably linked to a sequence that encodes an unpolyadenylated RNA capable of reducing a phenotypic expression of a nucleic acid of interest, the unpolyadenylated RNA comprising: a target-specific sense nucleotide sequence, a target-specific antisense nucleotide sequence, and a spacer nucleotide sequence located between said sense and antisense nucleotide sequence, wherein the target-specific antisense nucleotide sequence comprises 20 consecutive nucleotides having 100% sequence identity to a sequence complementary to a sequence of 20 consecutive nucleotides of an untranslated region of an RNA molecule transcribed or produced from the nucleic acid of interest which is normally capable of being expressed in the cell, and wherein the target-specific sense nucleotide sequence and the target-specific antisense nucleotide sequence form an artificial hairpin with each other. 26. The plant cell of claim 25, wherein the cell is a cell in culture. 27. The cell of claim 25, wherein the phenotypic expression of the nucleic acid of interest is reduced relative to a corresponding cell lacking said unpolyadenylated RNA. 28. The cell of claim 25, which has a modified phenotype compared to a corresponding cell lacking said unpolyadenylated RNA. 29. The cell of claim 28, wherein the modified phenotype is a modified profile of metabolites synthesized in the cell. 30. The cell of claim 25, wherein the plant cell is a cell of a monocotyledonous plant. 31. The cell of claim 25, wherein the plant cell is a cell of a dicotyledonous plant. 32. The cell of claim 30, wherein the monocotyledonous plant is corn, rice, wheat, barley, or sugarcane. 33. The cell of claim 31, wherein the dicotyledonous plant is cotton, oilseed rape, soybean, a vegetable, chicory, a brassica vegetable, lettuce, tomato, tobacco, potato, or sugarbeet. 34. A transgenic plant, comprising a chimeric DNA molecule comprising a promoter which is operable in a cell of the plant, the promoter being operably linked to a sequence encoding an unpolyadenylated RNA capable of reducing the expression of a nucleic acid of interest, the unpolyadenylated RNA comprising a target-specific sense nucleotide sequence, a target-specific antisense nucleotide sequence, a spacer nucleotide sequence located between said sense and antisense sequence, wherein the target-specific antisense nucleotide sequence comprises 20 consecutive nucleotides having 100% sequence identity to a sequence complementary to a sequence of 20 consecutive nucleotides of an untranslated region of an RNA molecule transcribed or produced from a nucleic acid of interest which is normally capable of being expressed in the cell, and wherein the target-specific sense nucleotide sequence and the target-specific antisense nucleotide sequence form an artificial hairpin with each other. 35. The transgenic plant of claim 34, wherein the plant is a monocotyledonous plant. 36. The transgenic plant of claim 34, wherein the plant is a dicotyledonous plant. 37. The transgenic plant of claim 35, wherein the monocotyledonous plant is corn, rice, wheat, barley, or sugarcane. 38. The transgenic plant of claim 36, wherein the dicotyledonous plant is cotton, oilseed rape, soybean, a vegetable, chicory, a brassica vegetable, lettuce, tomato, tobacco, potato, or sugarbeet. 39. The transgenic plant of claim 34, wherein the plant has a modified phenotype compared to a corresponding plant which is lacking said unpolyadenylated RNA. 40. The transgenic plant of claim 39, wherein the modified phenotype is shatter resistance, a modified pattern of flower color, nematode resistance, delayed fruit ripening, male sterility, a reduced level of a secondary metabolite, reduced expression of a gene involved carbohydrate metabolism or lipid biosynthesis, delayed senescence, altered lignification, altered fibre quality in cotton, or increased bruising resistance in potato by reduced polyphenoloxidase. 41. The method of claim 1 wherein the target-specific antisense nucleotide sequence consists of at least 20 consecutive nucleotides having 100% sequence identity to a sequence complementary to a sequence consisting of at least 20 consecutive nucleotides of an untranslated region of an RNA molecule transcribed or produced from said nucleic acid of interest. 42. The chimeric DNA molecule of claim 17 wherein the target-specific antisense nucleotide sequence consists of at least 20 consecutive nucleotides having 100% sequence identity to a sequence complementary to a sequence consisting of at least 20 consecutive nucleotides of an untranslated region of an RNA molecule transcribed or produced from said nucleic acid of interest. 43. The plant cell of claim 25, wherein the target-specific antisense nucleotide sequence consists of at least 20 consecutive nucleotides having 100% sequence identity to a sequence complementary to a sequence consisting of at least 20 consecutive nucleotides of an untranslated region of an RNA molecule transcribed or produced from said nucleic acid of interest. 44. The transgenic plant of claim 34, wherein the target-specific antisense nucleotide sequence consists of at least 20 consecutive nucleotides having 100% sequence identity to a sequence complementary to a sequence consisting of at least 20 consecutive nucleotides of an untranslated region of an RNA molecule transcribed or produced from said nucleic acid of interest. 45. The method of claim 1, wherein said spacer nucleotide sequence consists of 4 nucleotides to 200 nucleotides. 46. The chimeric DNA molecule of claim 17, wherein said spacer nucleotide sequence consists of 4 nucleotides to 200 nucleotides. 47. The plant cell of claim 25, wherein said spacer nucleotide sequence consists of 4 nucleotides to 200 nucleotides. 48. The transgenic plant of claim 34, wherein said spacer nucleotide sequence consists of 4 nucleotides to 200 nucleotides.

Details for Patent 9,399,777

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2019-08-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2019-08-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2019-08-13